A recent report has shown that multiplexed immunofluorescence (mIF) assays can outperform GESs, tumor mutational burden, and PD-L1 expression (measured by standard IHC) for predicting response to checkpoint inhibition across several tumor types21. This evidence concerns the gene CD274 and neoplasm.